Latest:
Carol Bush on the MCA Telehealth Network
Carol Bush, BS, RN, from the The University of Kansas Cancer Center, on the Midwest Cancer Alliance Telehealth Network
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Carolina Moreno Atanasio, MD
Latest:
Dr. Atanasio on Ibrutinib and Obinuzutumab Combination in CLL/SLL
Carolina Moreno Atanasio, MD, University of Barcelona, discusses an ongoing phase III study comparing ibrutinib and obinutuzumab with chlorambucil and obinutuzumab in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Caroline Robert, MD, PhD
Latest:
Dr. Robert on Potential of Dabrafenib/Trametinib in Melanoma Brain Metastases
Caroline Robert, MD, PhD, head of the Dermatology Unit at the Institut Gustave-Roussey, co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University, explains why patients with melanoma and brain metastases were excluded from a trial evaluating the efficacy of dabrafenib plus trametinib.
Caroline Seymour
Managing Editor,
Latest:
Dr Secord on the National Academies of Sciences, Engineering, and Medicine’s Assessment of Women’s Health Research at the NIH
Angeles Alvarez Secord, MD, MHSc, discusses findings from the consensus report published by the National Academies of Sciences, Engineering, and Medicine committee.
Carolyn D. Britten, MD
Latest:
Dr. Carolyn Britten on Next Steps in Immunotherapy
Carolyn D. Britten, MD, chief, Division of Hematology Oncology, associate director, Clinical Investigations, at the Hollings Cancer Center, Medical University of South Carolina, discusses questions that remain in immunotherapy.
Carryn Anderson, MD
Latest:
Dr. Anderson on Superoxide Dismutase Mimetic GC4419 in Treating Patients With Oropharyngeal Carcinoma
Carryn Anderson, MD, assistant professor of Radiation Oncology, University of Iowa, discusses a phase Ib/IIa study of superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavitiy or oropharyngeal carcinoma.